|
eNOS
Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1. Belongs to the NOS family. Platelets, placenta, liver and kidney. 3 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.
|
| Protein type: Amino Acid Metabolism - arginine and proline; EC 1.14.13.39; Oxidoreductase |
| Chromosomal Location of Human Ortholog: 5 A3|5 11.32 cM |
|
Cellular Component:
apical part of cell; caveola; cytoplasm; cytoskeleton; cytosol; Golgi apparatus; membrane; membrane raft; mitochondrion; nucleolus; nucleus; plasma membrane; sarcolemma; vesicle membrane
|
|
Molecular Function:
actin binding; actin monomer binding; arginine binding; beta-catenin binding; cadherin binding; calmodulin binding; flavin adenine dinucleotide binding; FMN binding; heme binding; Hsp90 protein binding; metal ion binding; NADP binding; NADPH-hemoprotein reductase activity; nitric-oxide synthase activity; nitric-oxide synthase binding; oxidoreductase activity; scaffold protein binding; tetrahydrobiopterin binding
|
|
Biological Process:
angiogenesis; aortic valve morphogenesis; arginine catabolic process; blood vessel remodeling; cellular response to mechanical stimulus; cellular response to transforming growth factor beta stimulus; endocardial cushion morphogenesis; endothelial cell migration; homeostasis of number of cells within a tissue; in utero embryonic development; lipopolysaccharide-mediated signaling pathway; lung development; negative regulation of biomineral tissue development; negative regulation of blood pressure; negative regulation of calcium ion transport; negative regulation of cell proliferation; negative regulation of hydrolase activity; negative regulation of muscle hyperplasia; negative regulation of potassium ion transport; negative regulation of smooth muscle cell proliferation; nitric oxide biosynthetic process; nitric oxide mediated signal transduction; ovulation from ovarian follicle; positive regulation of angiogenesis; positive regulation of apoptotic process; positive regulation of blood vessel endothelial cell migration; positive regulation of gene expression; positive regulation of guanylate cyclase activity; pulmonary valve morphogenesis; regulation of blood vessel size; regulation of neurological system process; regulation of sodium ion transport; regulation of systemic arterial blood pressure by endothelin; regulation of the force of heart contraction by chemical signal; removal of superoxide radicals; response to estradiol; response to hormone; response to lipopolysaccharide; signal transduction; smooth muscle hyperplasia; ventricular septum morphogenesis
|
|
Reference #:
P70313
(UniProtKB)
|
|
Alt. Names/Synonyms: 2310065A03Rik; cNOS; Constitutive NOS; EC-NOS; Ecnos; endothelial nitric oxide synthase; Endothelial NOS; eNOS; nitric oxide synthase 3, endothelial cell; Nitric oxide synthase, endothelial; NOS type III; Nos-3; Nos3; NOSIII; OTTMUSP00000028591
|
|
Gene Symbols: Nos3
|
|
Molecular weight:
132,916 Da
|
|
Basal Isoelectric point:
6.61
Predict pI for various phosphorylation states
|
|
CST Pathways:
AMPK Signaling
|
Angiogenesis
|
PI3K/Akt Signaling
|
Protein-Specific Antibodies, siRNAs or Recombinant Proteins from Cell Signaling Technology®
|
